Ipamorelin and MK-677 (ibutamoren) both stimulate growth hormone (GH) release via the ghrelin receptor (GHSR1a), but their pharmacological profiles differ dramatically. Ipamorelin is a selective peptidomimetic with minimal off-target effects, while MK-677 is a non-peptide with significant cortisol co-secretion. These differences define their respective therapeutic windows, safety profiles, and clinical applications.
Pharmacological Classification
Section titled “Pharmacological Classification”Ipamorelin
Section titled “Ipamorelin”Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) classified as a selective growth hormone secretagogue (GHS). It is the most pharmacologically refined GHS available, demonstrating high GHSR1a selectivity with negligible effects on cortisol, ACTH, prolactin, or aldosterone.
- Molecular class: Pentapeptide (peptidomimetic)
- Receptor target: GHSR1a (ghrelin receptor)
- Selectivity: High — GHSR1a-selective
- Route: Subcutaneous, intravenous
- Oral bioavailability: <5% (peptide degradation)
MK-677 (Ibutamoren)
Section titled “MK-677 (Ibutamoren)”MK-677 is a non-peptide benzylpiperazine-urea derivative that also activates GHSR1a but with a broader pharmacological profile. It additionally stimulates cortisol, ACTH, aldosterone, and prolactin secretion — off-target effects that limit its clinical utility.
- Molecular class: Non-peptide (benzylpiperazine)
- Receptor target: GHSR1a (ghrelin receptor) + adrenal effects
- Selectivity: Low — broad GHSR1a activation
- Route: Oral
- Oral bioavailability: ~60–70% (non-peptide, acid-stable)
Mechanism of Action
Section titled “Mechanism of Action”Ipamorelin: Selective GHSR1a Agonism
Section titled “Ipamorelin: Selective GHSR1a Agonism”Ipamorelin binds GHSR1a with high affinity (EC₅₀ ~0.7 nM) and activates the Gq/PLC/IP₃/Ca²⁺ signaling cascade, stimulating GH release from somatotrophs. The defining feature is selectivity: ipamorelin activates GHSR1a without significantly stimulating cortisol, ACTH, prolactin, or aldosterone secretion.
Ipamorelin promotes pulsatile GH release that mimics physiological secretion patterns:
- Pulse frequency: Maintained at physiological rate (6–8 pulses/24 hrs)
- Pulse amplitude: Increased 2–3-fold above baseline
- Peak GH levels: 15–25 ng/mL per pulse
- Inter-pulse troughs: Return toward baseline
- IGF-1 elevation: Moderate, sustained (15–25% above baseline)
MK-677: Non-selective GHSR1a Activation
Section titled “MK-677: Non-selective GHSR1a Activation”MK-677 binds GHSR1a with an EC₅₀ of ~1.3 nM and additionally stimulates:
- Cortisol secretion: Significant ACTH and cortisol elevation (30–50% AUC increase)
- Aldosterone elevation: Via adrenal GHSR1a activation
- Prolactin: Modest increase
- IGF-1 elevation: Sustained rather than pulsatile
MK-677 produces sustained (non-pulsatile) GH elevation, with plasma GH remaining chronically elevated rather than exhibiting discrete pulses. This non-physiological pattern may produce different downstream effects than pulsatile stimulation.
Comparison Table
Section titled “Comparison Table”| Property | Ipamorelin | MK-677 |
|---|---|---|
| Structure | Pentapeptide | Non-peptide (benzylpiperazine) |
| GHSR1a EC₅₀ | ~0.7 nM | ~1.3 nM |
| Receptor selectivity | High (GHSR1a selective) | Low (GHSR1a + adrenal) |
| Cortisol elevation | <10% | 30–50% |
| ACTH elevation | Minimal | Significant |
| Prolactin elevation | Minimal | Mild |
| GH release pattern | Pulsatile | Sustained (non-pulsatile) |
| Half-life | ~2 hrs (IV), ~1 hr (SC) | ~1–2 hrs (oral) |
| Oral bioavailability | <5% | ~60–70% |
| Route | SC, IV | Oral |
| Steady state | N/A (acute pulses) | 2–3 days |
Cortisol and Safety Profile
Section titled “Cortisol and Safety Profile”Ipamorelin: Cortisol-Neutral
Section titled “Ipamorelin: Cortisol-Neutral”Ipamorelin’s cortisol-neutral profile is its primary safety advantage:
- Cortisol AUC change: <10% increase from baseline
- ACTH change: Not significantly different from placebo
- Aldosterone: No significant change
- Prolactin: No significant change
The selectivity is attributed to ipamorelin’s specific interaction with the GHSR1a transmembrane binding pocket, which differs from the broader conformational changes induced by ghrelin or non-selective secretagogues.
MK-677: Cortisol Elevation
Section titled “MK-677: Cortisol Elevation”MK-677 produces clinically significant cortisol elevation:
- Cortisol AUC increase: 30–50% in dose-ranging studies
- ACTH elevation: Parallel increase in plasma ACTH
- Dose-dependent: Greater cortisol elevation at higher doses (25 mg)
- Chronic exposure: Cortisol elevation persists with continued dosing
- Clinical concern: Long-term cortisol elevation may promote insulin resistance, visceral adiposity, and immunosuppression
This cortisol co-secretion is the primary safety concern limiting MK-677’s clinical utility.
GH Release Patterns
Section titled “GH Release Patterns”Ipamorelin: Pulsatile Release
Section titled “Ipamorelin: Pulsatile Release”Ipamorelin stimulates discrete GH pulses that mirror physiological secretion:
- Peak GH levels: 15–25 ng/mL per pulse
- Pulse duration: 1–2 hours
- Return to baseline: Between pulses
- IGF-1 response: Moderate elevation (15–25%)
- Physiological relevance: Maintains normal feedback regulation
MK-677: Sustained Elevation
Section titled “MK-677: Sustained Elevation”MK-677 produces chronic, non-pulsatile GH elevation:
- Sustained GH: 10–20 ng/mL (continuous)
- No discrete pulses: Flat pharmacokinetic profile
- IGF-1 response: Greater elevation (30–50%)
- Physiological relevance: Disrupts normal pulsatile regulation
- Receptor desensitization risk: Chronic stimulation may downregulate GHSR1a
Clinical Evidence
Section titled “Clinical Evidence”Ipamorelin
Section titled “Ipamorelin”- Phase II trials: Demonstrated significant IGF-1 elevation in GH-deficient adults
- Surgical stress: Reduced cytokine response and improved nitrogen balance in post-surgical patients
- Critical illness: Investigated for GH stimulation in ICU patients with promising results
- Body composition: Modest improvements in lean body mass in elderly subjects
- Safety: Well-tolerated in doses up to 30 µg/kg SC
MK-677
Section titled “MK-677”- Phase II/III trials: Demonstrated GH and IGF-1 elevation in elderly subjects and GH-deficient adults
- Body composition: Increased lean body mass and decreased adiposity in short-term studies
- Sleep: Improved slow-wave sleep in some studies
- Bone density: Modest improvements in IGF-1-dependent bone markers
- Safety concerns: Insulin resistance, fluid retention, and cortisol-related side effects limited development
Dosing Protocols
Section titled “Dosing Protocols”Ipamorelin
Section titled “Ipamorelin”| Indication | Dose | Route | Frequency | Timing |
|---|---|---|---|---|
| GH stimulation | 20–30 µg/kg | SC | 1–3× daily | Pre-sleep, fasting |
| Anti-aging | 100–300 µg | SC | 1× daily | Before bed |
| Post-surgical | 20–30 µg/kg | SC | 3× daily | Every 8 hrs |
| Research | 100–500 µg | SC | 1–2× daily | Varies |
MK-677
Section titled “MK-677”| Indication | Dose | Route | Frequency | Timing |
|---|---|---|---|---|
| GH stimulation | 10–25 mg | Oral | 1× daily | Before bed |
| Body composition | 25 mg | Oral | 1× daily | Evening |
| Research | 10–50 mg | Oral | 1× daily | Varies |
When to Choose Each
Section titled “When to Choose Each”Choose Ipamorelin When:
Section titled “Choose Ipamorelin When:”- Cortisol control is critical — ipamorelin’s selectivity avoids cortisol elevation
- Pulsatile GH release is desired — mimics physiological secretion patterns
- Long-term use is planned — safer profile for extended protocols
- Injection is acceptable — SC administration is well-tolerated
- Combination with GHRH analogs — ipamorelin + CJC-1295 is a popular stack
Choose MK-677 When:
Section titled “Choose MK-677 When:”- Oral administration is required — MK-677’s ~65% oral bioavailability is a major advantage
- GH stimulation is the sole goal — if cortisol effects are not a concern
- Short-term use — cortisol elevation may be acceptable for limited durations
- Research applications — MK-677’s oral route simplifies experimental protocols
Synergistic Stacking
Section titled “Synergistic Stacking”Ipamorelin + CJC-1295 (DAC)
Section titled “Ipamorelin + CJC-1295 (DAC)”The most common ipamorelin combination:
- Ipamorelin: 200–300 µg SC daily — stimulates GH pulses
- CJC-1295 DAC: 1–2 mg SC weekly — sustains GH pulse amplitude via GHRH potentiation
This stack produces synergistic GH elevation with maintained pulsatility and minimal cortisol effects. The combination is widely used in research settings for body composition and anti-aging studies.
MK-677 Solo
Section titled “MK-677 Solo”MK-677 is typically used alone due to its oral bioavailability and non-selective profile. Combining with GHRH analogs may enhance GH release but also amplifies cortisol concerns.
Limitations
Section titled “Limitations”- Ipamorelin: Requires injection; limited to research use; no FDA approval
- MK-677: Cortisol elevation limits long-term use; insulin resistance; oral route is convenient but off-target effects are significant
- Both: No large-scale Phase III trials; long-term safety data lacking; manufacturing quality varies